Heart disease. Hearing loss. Dependence. Chronic pain. Alzheimer’s. Als. These are some of the areas where Eli LillyRinse with money from her GLP-1 drugs wants to make big bets.
These are the ideas that “hide in sight,” said scientific director of Lilly Dan Skovronsky. These are places where other pharmaceutical companies may not want to go because they are problems that are difficult to solve.
“As at the moment, the largest health care company in the world, probably the largest health care company in the world of all time, we have an obligation,” said Skovronsky. “The investors have given us this vote of trust. We see this as an obligation to invest in some of these big problems that hide in sight, to try to make a difference for the health of your community.”
Lilly’s shooting, sold like Mounjaro for diabetes and Zepbound for obesity, transformed the company. Company sales have increased by almost 60% since Mounjaro was approved in 2022. The share price of Lilly has increased by 268% in the last three years, giving the company a market capitalization of $ 823 billions – the highest of all health care companies.
Now the company wants this success is reflected in other areas of disease.
Lilly is already testing if her medication Kisunla can prevent Alzheimer’s disease. Kisunla is a monoclonal antibody that eliminates the amyloid plates of the brain, which are associated with the disease that harass in memory. It is currently approved to treat people in the early stages of Alzheimer’s.
The company’s recruitment elders in churches, Walmart car parks and other sites to give them a blood test and see if they are at risk of illness. Some of the people at the trial will receive Kisunla and others will receive a placebo. Once enough participants receive a diagnosis of Alzheimer’s, Lilly will seek and see if there is a difference between people who have received his drugs and the people who received a placebo.
“If we can prevent it, even in half of the patients, it will be a revolution in the way we think of diagnosing and treating Alzheimer’s disease,” said Skovronsky. “This would probably mark a major inflection point in the way these types of drugs are used.”
A bottle of Alzheimer’s drug from Eli Lilly sold under the Kisunla brand.
Source: Eli Lilly
Lilly also invests massively in gene therapy at a time when the field is faced with significant uncertainty. Last summer, the company opened the $ 700 million Lilly Institute for Genetic Medicine in Boston, far from the headquarters of Lilly in Indianapolis and in one of the American epicentres for this work.
Large biopharmatic companies and small people find it difficult to transform the potential of scientific breakthroughs such as CRISPR-CAS9 genetic publishing technology into successful drugs. One of the Holdops was how to get the treatments in their destinations inside the body or delivery, as we know in the industry.
“The reality is that local delivery will be a kind of small application to human health, but once we have cracked this, and I think Lily is the company that can break it, because when we think of delivering to Other fabrics are not just genetic medicine, how is it packaging it?
Lilly is only positioned to make the big swings. It remains to be seen if it can strike them.